These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 36870360)

  • 21. Single-Agent Neoadjuvant Immunotherapy With a PD-1 Antibody in Locally Advanced Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer.
    Pei F; Wu J; Zhao Y; He W; Yao Q; Huang M; Huang J
    Clin Colorectal Cancer; 2023 Mar; 22(1):85-91. PubMed ID: 36528470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
    Hofheinz RD; Wenz F; Post S; Matzdorff A; Laechelt S; Hartmann JT; Müller L; Link H; Moehler M; Kettner E; Fritz E; Hieber U; Lindemann HW; Grunewald M; Kremers S; Constantin C; Hipp M; Hartung G; Gencer D; Kienle P; Burkholder I; Hochhaus A
    Lancet Oncol; 2012 Jun; 13(6):579-88. PubMed ID: 22503032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.
    Li Y; Pan C; Gao Y; Zhang L; Ji D; Cui X; Zhang X; Cai Y; Zhang Y; Yao Y; Wang L; Leng J; Zhan T; Wu D; Gao Z; Sun YS; Li Z; Luo H; Wu A
    JAMA Surg; 2024 May; 159(5):529-537. PubMed ID: 38381429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons].
    Sun TT; Wang L; Yao YF; Peng YF; Zhao J; Zhan TC; Leng JH; Wang HY; Chen N; Chen PJ; Li YJ; Zhang X; Liu XZ; Zhang Y; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):550-559. PubMed ID: 31238634
    [No Abstract]   [Full Text] [Related]  

  • 31. First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial.
    Tian XP; Cai J; Xia Y; Zhang YC; Wang L; Liu PP; Huang HQ; Li YJ; Zhou H; Li ZM; Yang J; Wei LQ; Zou QH; Huang Y; Li J; Ling L; Zhong WL; Cai QQ
    Lancet Haematol; 2024 May; 11(5):e336-e344. PubMed ID: 38554717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.
    Li K; Chen J; Hu Y; Wang YZ; Shen Y; Chen G; Peng W; Fang Z; Xia B; Chen X; Song K; Wang Y; Zou D; Wang YC; Han Y; Feng X; Yuan J; Guo S; Meng X; Feng C; Chen Y; Yang J; Fan J; Wang J; Ai J; Ma D; Sun C
    Lancet Oncol; 2024 Jan; 25(1):76-85. PubMed ID: 38048802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
    Lee JB; Kim HS; Jung I; Shin SJ; Beom SH; Chang JS; Koom WS; Kim TI; Hur H; Min BS; Kim NK; Park S; Jeong SY; Baek JH; Kim SH; Lim JS; Lee KY; Ahn JB
    Trials; 2020 Apr; 21(1):320. PubMed ID: 32264919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
    Yang R; Wu T; Yu J; Cai X; Li G; Li X; Huang W; Zhang Y; Wang Y; Yang X; Ren Y; Hu R; Feng Q; Ding P; Zhang X; Li Y
    Front Immunol; 2023; 14():1182299. PubMed ID: 37441082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
    Zhang X; Yang R; Wu T; Cai X; Li G; Yu K; Li Y; Ding R; Dong C; Li J; Hu R; Feng Q; Li Y
    Front Immunol; 2022; 13():913483. PubMed ID: 35958603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short-term outcomes of neoadjuvant chemotherapy with capecitabine plus oxaliplatin for patients with locally advanced rectal cancer followed by total or tumor-specific mesorectal excision with or without lateral pelvic lymph node dissection.
    Sakamoto W; Kanke Y; Onozawa H; Okayama H; Endo H; Fujita S; Saito M; Saze Z; Momma T; Kono K
    Fukushima J Med Sci; 2022 Aug; 68(2):89-95. PubMed ID: 35732415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
    Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
    BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multicenter real-world study on safety and efficacy of neoadjuvant therapy in combination with immunotherapy for colorectal cancer].
    Liu XZ; Xiong Z; Xiao BY; Yu GY; Li YJ; Yao YF; Tao KX; Ding PR; Zhang W; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Mar; 25(3):219-227. PubMed ID: 35340171
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.